Literature DB >> 24565780

Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.

Samar Ojaimi1, Paul R Harnett2, David A Fulcher3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24565780     DOI： 10.1016/j.jaip.2013.08.009

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI).

Authors:  D Ferastraoaru; H J Bax; C Bergmann; M Capron; M Castells; D Dombrowicz; E Fiebiger; H J Gould; K Hartmann; U Jappe; G Jordakieva; D H Josephs; F Levi-Schaffer; V Mahler; A Poli; D Rosenstreich; F Roth-Walter; M Shamji; E H Steveling-Klein; M C Turner; E Untersmayr; S N Karagiannis; E Jensen-Jarolim
Journal:  Clin Transl Allergy       Date:  2020-07-17       Impact factor: 5.871

Review 3.  Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes.

Authors:  Karen S Hsu Blatman; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 4.  Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.

Authors:  Joana Caiado; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2021-07-07       Impact factor: 4.806

5.  Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study.

Authors:  Hanneke N G Oude Elberink; Mathilde Jalving; Hilda Dijkstra; Annick A J M van de Ven
Journal:  Clin Transl Allergy       Date:  2020-01-29       Impact factor: 5.871

Review 6.  Human(ized) monoclonal antibodies in atopic patients - state of the art.

Authors:  Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

7.  The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer.

Authors:  Alessandra Vultaggio; Maria Cristina Petrella; Federica Tomao; Francesca Nencini; Valentina Mecheri; Andrea Marini; Margherita Perlato; Emanuele Vivarelli; Claudia De Angelis; Ilaria Ferrarini; Serena Pillozzi; Andrea Matucci; Lorenzo Antonuzzo
Journal:  Gynecol Oncol Rep       Date:  2021-10-12

Review 8.  Omalizumab for successful chemotherapy desensitisation: What we know so far.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Sabina Loredana Corcea; Luiza Spiru; Cornelia Nitipir; Victor Strambu; Dragos Bumbacea
Journal:  Clin Transl Allergy       Date:  2021-12-13       Impact factor: 5.871

Review 9.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.